Sarcomatoid Renal Cell Carcinoma Arisen after the Renal Allograft from Donation after Citizen Death: A Case Report and Literature Review
Journal of Surgery
Volume 4, Issue 5, October 2016, Pages: 122-125
Received: Aug. 28, 2016; Accepted: Sep. 12, 2016; Published: Oct. 8, 2016
Views 3264      Downloads 103
Authors
Wu Yonglu, Department of Urology, First Affiliated Hospital of Jinan University, Guangzhou, China
Chen Jie, Department of Urology, First Affiliated Hospital of Jinan University, Guangzhou, China
Yuan Boxiang, Department of Urology, First Affiliated Hospital of Jinan University, Guangzhou, China
Su Zexuan, Department of Urology, First Affiliated Hospital of Jinan University, Guangzhou, China
Ding Hongwen, Department of Urology, First Affiliated Hospital of Jinan University, Guangzhou, China
Shi Liping, Department of Urology, First Affiliated Hospital of Jinan University, Guangzhou, China
Wang Shaojiang, Department of Urology, First Affiliated Hospital of Jinan University, Guangzhou, China
Article Tools
Follow on us
Abstract
The aim of this study was to discuss the causes and preventions of sacromatoid renal cell carcinoma (SRCC) after renal allograft from donation after citizens death (DCD). It was reported on a 45-year-old male patient had undergone renal transplantation in other hospital because of chronic renal insufficiency uraemia in August of 2014. Two months later, lesions found in the renal parenchyma in the right iliac fossa via the color doppler ultrasound. The area of renal transplantation was bulged with tenderness. The renal dysfunction and microscopic haematuria were found. The review color doppler ultrasound and CT showed that the allograft kidney is enlarged rapidly. On 22nd December 2014, a surgical exploration was performed. An irregular and hard mass within the parenchyma of engrafted kidney was found, which was considered as malignant. The nephrectomy of the renal allograft was performed in the operation. First postoperative day, his condition was deteriorating rapidly. Finally, the patient died of cardiac functional failure. The tumor was pathologically diagnosed as sacromatoid renal cell carcinoma (SRCC). SRCC found in the donor allograft kidney is highly malignant and poorly prognosis. The repeated imaging investigations are necessary to exclude the hidden trouble of tumors, such as SRCC. Postoperative immunosuppressive regimens should be modified and the screening program of renal tumor for the early control and prevention should be strengthen.
Keywords
Organ Donation, Renal Allograft, Sarcomatoid Renal Cell Carcinoma
To cite this article
Wu Yonglu, Chen Jie, Yuan Boxiang, Su Zexuan, Ding Hongwen, Shi Liping, Wang Shaojiang, Sarcomatoid Renal Cell Carcinoma Arisen after the Renal Allograft from Donation after Citizen Death: A Case Report and Literature Review, Journal of Surgery. Vol. 4, No. 5, 2016, pp. 122-125. doi: 10.11648/j.js.20160405.16
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Kauffman H M, McBride M A, Cherikh W S, et al. Transplant tumor registry: donor related malignancies. Transplantation, 2002, 74 (3): 358-362.
[2]
Hwang JK, Moon IS, Kim JI. Malignancies after kidney transplantation: a 40-year single-center experience in Korea. Transpl Int 2011; 24: 716-21.
[3]
Wang Chao, Li Tao, Zhang Jian, Liu Fen, Xie Zelin, Tang Yawang, et al. Trend analysis of malignant tumor after renal transplantation in China. Organ Transplantation 2015; 3: 169-73.
[4]
Pedotti P, Cardillo M, Rossini G, Arcuri V, Boschiero L, Caldara R, et al. Incidence of cancer after kidney transplant: results from the North Italy transplant program. Transplantation 2003; 76: 1448-51.
[5]
Tillou X, Guleryuz K, Doerfler A, Bensadoun H, Chambade D, Codas R, et al. Nephron sparing surgery for De Novo kidney graft tumor: results from a multicenter national study. American Journal of Transplantation 2014; 14: 2120-5.
[6]
Cornelis F, Buy X, André M, Oyen R, Bouffard-Vercelli J, Blandino A, et al. De novo renal tumors arising in kidney transplants: midterm outcome after percutaneous thermal ablation. Radiology 2011; 260: 900-7.
[7]
Schulz TF. Cancer and viral infections in immunocompromised individuals. International journal of cancer 2009; 125: 1755-63.
[8]
Nalesnik MA, Ison MG. Organ transplantation from deceased donors with cancer: is it safe? Open Access Surgery 2011; 4: 11-20.
[9]
Wein AJ, Kavoussi LR,Novick AC,Partin AW, Peters CA. Renal Tumors.In: Guo Yinglu, Zhou Liqun, editor. Campbell-Walsh Urology, 9th ed. Peking: Peking University Medical Press; 2009.p.1651-773.
[10]
Kauffman H M, Cherikh W S, McBride M A, et al. Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update. Transplantation, 2007, 84 (2): 272-274.
[11]
Penn I. Primary kidney tumors before and after renal transplantation.T ransplantation, 1995, 59 (4): 480-485.
[12]
De Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. The American journal of surgical pathology 2001; 25: 275-84.
[13]
Ro JY, Ayala AG, Sella A, Samuels ML, Swanson DA. Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases. Cancer 1987; 59: 516-26.
[14]
Akhtar M, Tulbah A, Kardar A H, Ali MA. Sarcomatoid renal cell carcinoma: the chromophobe connection. The American journal of surgical pathology 1997; 21: 1188-95.
[15]
Xu Hongmin, Li Weihua, Li Hongfen. The expression of cytokeratin and vimentin immunohistochemistry in renal cell carcinoma. Medical Journal of Chinese People's Liberation Army 1988; 3:177-9.
[16]
Luo Ming, Qiu Jian-xin. Mammalian target of rapamycin inhibitors in the treatment of malignancy after organ transplantation. World clinical drugs 2009:02:65-71.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186